CareDx, Inc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Walter Hanna Jr.
- Full Time Employees
- 763
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 8000 Marina Boulevard Brisbane CA United States of America 94005
- IPO Date
- Jul 17, 2014
- CIK
- 0001217234
- Website
- caredx.com
- Similar Companies
- Business
- CareDx, Inc. CareDx, Inc. (Nasdaq: CDNA) operates as a leading precision medicine company focused on the discovery, development, and commercialization of diagnostic solutions, testing services, products, and digital healthcare tools for transplant patients and caregivers along the pre- and post-transplant journey. The company offers core products and services including AlloSure Kidney, AlloSure Heart, AlloSure Lung, and AlloMap Heart gene expression profiling tests, which utilize donor-derived cell-free DNA (dd-cfDNA) for noninvasive surveillance to detect organ injury and rejection in kidney, heart, and lung transplant recipients; AlloSeq and QTYPE for superior HLA typing with hybrid capture technology; HeartCare, combining AlloMap Heart and AlloSure Heart; digital solutions such as the AlloCare mobile app for patient medication management, health tracking, and care coordination, and transplant administration software like Ottr acquired via TransChart in 2021; transplant lab products for matching; and pharma services to accelerate biopharma clinical development. Founded in 1998 and headquartered in Brisbane, California, with principal operations in South San Francisco, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden, CareDx primarily generates revenue from the United States while serving over 150 U.S. transplant centers and more than 30,000 patients. Recent developments include the launch of AlloSure Plus (formerly AlloView), an AI-driven diagnostic platform integrating dd-cfDNA with clinical methods for improved rejection prediction; new IVD products and IVDR certification for AlloSeq Tx and QTYPE announced at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting; the launch of HistoMap Kidney, a tissue-based gene expression assay to characterize rejection phenotypes, planned for early 2026; partnerships such as with Leidos to transform the Organ Procurement and Transplantation Network, TC BioPharm for AML therapy trials using AlloCell testing, and agreements with Illumina and Cibiltech; installation of the EPIC environment and customer pilots; and strong Q3 2025 financial results with 21% revenue growth, 30% increase in patient and digital solutions revenue, and improved profitability.
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why CareDx Stock Jumped Today
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CareDx Q2 Earnings Call Highlights
CareDx Announces Second Quarter 2026 Financial Results
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
CareDx's Growth Prospects With Naveris Keep Me Bullish
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx's CEO Sells 17K Shares
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?